Sunshine Biopharma Enters Material Definitive Agreement

TL;DR

**SBFM just signed a big deal, details pending, could be a game-changer.**

AI Summary

Sunshine Biopharma, Inc. (SBFM) filed an 8-K on February 12, 2024, reporting an "Entry into a Material Definitive Agreement" on February 11, 2024. This filing indicates a significant new agreement that could impact the company's operations or financial standing. For investors, this matters because material agreements often signal new business ventures, partnerships, or financing, which can affect future revenue, expenses, and ultimately, the stock price.

Why It Matters

This filing signals a potentially significant business development for Sunshine Biopharma, which could influence its financial performance and stock valuation.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its nature and impact.

Analyst Insight

Investors should monitor Sunshine Biopharma (SBFM) for subsequent filings or press releases that provide specific details about the 'Material Definitive Agreement' to assess its potential impact on the company's financials and future prospects.

Key Numbers

• $0.001 — Common Stock Par Value (The par value of Sunshine Biopharma's common stock.)

Key Players & Entities

• Sunshine Biopharma, Inc. (company) — the registrant filing the 8-K
• February 11, 2024 (date) — date of the earliest event reported
• February 12, 2024 (date) — date the 8-K was filed
• Nasdaq Stock Market LLC (company) — exchange where SBFM common stock and warrants are registered
• $0.001 (dollar_amount) — par value of common stock

Forward-Looking Statements

• Sunshine Biopharma will release further details about the material definitive agreement. (Sunshine Biopharma, Inc.) — high confidence, target: 2024-03-15

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
• $2,361,596 — lder for an aggregate purchase price of $2,361,596. Upon the closing of the May 2023 Warra
• $0.08 — l 2022 Warrants for a purchase price of $0.08 per April 2022 Warrant, for an aggregat
• $778,055 — ant, for an aggregate purchase price of $778,055. Upon the closing of the April 2022 War

Filing Documents

• sunshine_8k.htm (8-K) — 27KB
• sunshine_ex1001.htm (EX-10.1) — 12KB
• sunshine_ex1002.htm (EX-10.2) — 13KB
• 0001683168-24-000865.txt ( ) — 269KB
• sbfm-20240211.xsd (EX-101.SCH) — 3KB
• sbfm-20240211_def.xml (EX-101.DEF) — 26KB
• sbfm-20240211_lab.xml (EX-101.LAB) — 36KB
• sbfm-20240211_pre.xml (EX-101.PRE) — 25KB
• sunshine_8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On February 11, 2024, Sunshine Biopharma, Inc. (the "Company") entered into a securities purchase agreement (the "May 2023 Warrant Purchase Agreement") with the holder of the warrants, dated May 16, 2023 (the "May 2023 Warrants") to purchase 11,904,762 shares of common stock of the Company. Pursuant to the May 2023 Warrant Purchase Agreement, the Company bought back the May 2023 Warrants from the holder for an aggregate purchase price of $2,361,596. Upon the closing of the May 2023 Warrant Purchase Agreement, which occurred on February 12, 2024, the Company paid the purchase price to the holder, and the May 2023 Warrants were deemed cancelled and terminated in all respects. In addition, the holder waived the prohibition against variable rate transactions under the securities purchase agreement, dated May 12, 2023, between the Company and the holder. On February 11, 2024, the Company entered into securities purchase agreements (the "April 2022 Warrant Purchase Agreements") with the holders of warrants, dated April 28, 2022 (the "April 2022 Warrants") to purchase an aggregate of 9,725,690 shares of common stock of the Company. Pursuant to the April 2022 Warrant Purchase Agreements, the Company bought back from the holders the April 2022 Warrants for a purchase price of $0.08 per April 2022 Warrant, for an aggregate purchase price of $778,055. Upon the closing of the April 2022 Warrant Purchase Agreements, which occurred on February 12, 2024, the Company paid the purchase price to the holders, and the April 2022 Warrants were deemed cancelled and terminated in all respects.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 May 2023 Warrant Purchase Agreement 10.2 Form of April 2022 Warrant Purchase Agreement 104 Cover Page Interactive Data File (formatted in iXBRL) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 12, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR